1. American College of Rheumatology Ad Hoc Committee On Clinical Guidelines. Guidelines for the management of rheumatoid arthritis; 2002 Update. Arthritis Rheum 2002;46:328-346.
2. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road. Arthritis Rheum 2008;59:757-759.
3. American College of Rheumatology Ad Hoc Committee On Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-722.
5. Wilske KR, Healey LA. Remodeling the Pyramid-a Concept Whose Time Has Come. J Rheumatol 1989;16:565-567.
6. In: Klippel JH, Stone JH, Crofford LJ, White PH, editor. Chapter 41, Nonsteroidal anti-inflammatory drugs. Primer on the Rheumatic Diseases 2008;13th ed. Atlanta: Arthritis Foundation. 634-643.
7. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-314.
8. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomized trial. Lancet 2010;376:173-179.
9. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009;338:b702.
10. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-157.
11. In: Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, Loscalzo J, editor. Chapter 316, Rheumatoid arthritis. Harrison's Principles of Internal Medicine(Korean Language Edition) 2009;17th ed. McGraw-Hill. 2506-2516.
12. In: Hochberg MC, Silman AJ, editor. Chapter 42, Disease-modifying antirheumatic drugs 2:sulfasalazine. Rheumatology 2008;4th ed. London: Mosby. 437-447.
14. In: Hochberg MC, Silman AJ, editor. Chapter 44 , Disease-modifying antirheumatic drugs 4:leflunomide. Rheumatology 2008;4th ed. London: Mosby. 461-469.
15. In: Hochberg MC, Silman AJ, editor. Chapter 47, Other drugs in rheumatic disease. Rheumatology 2008;4th ed. London: Mosby. 487-493.
16. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-768.
19. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russel A, Saag KG, Svensson B, Westhoven R, Zeidler H, Bijlsma JW. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-1567.